Clinical trial · Observational
Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A positive Anti-Neutrophil Cytoplasm Antibody (ANCA) test administered to patients with a high probability for vasculitis has high sensitivity and specificity for vasculitis. A positive ANCA test result in those patients who do not have a high probability for vasculitis requires extensive follow-up because those patients eventually present with malignancy or other inflammatory diseases. The investigators wish to investigate the correlation between the differing levels of positive ANCA tests and their relationship to vasculitis, malignancy and inflammatory diseases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Follow-up | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Positive ANCA
- description
- Patients with borderline positive ANCA results.
- interventionNames
- Other: Follow-up
Primary outcomes (1)
- measure
- Borderline Positive ANCA
- timeFrame
- Two weeks
- description
- Borderline positive ANCA results of 12-19 U/ml is indication of possible malignancy or inflammatory diseases
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with borderline positive ANCA test results Exclusion Criteria: * Pregnant
References
Publications (0)
Data not yet available